Company ProfilePremium

Neelikon Food Dyes & Chemicals Ltd.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Neelikon Food Dyes & Chemicals Ltd. - Company showcase

Year Founded & Workforce

1983

261 Employees

Neelikon Food Dyes & Chemicals Ltd. logo

Neelikon Food Dyes & Chemicals Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Neelikon Food Dyes & Chemicals Ltd. Overview

Neelikon is a Mumbai-headquartered, promoter-owned specialty colourant manufacturer. It has a four-decade record in high-purity synthetic food, drug and cosmetic (FD&C / D&C) dyes and lakes. It also makes specialty fluorescent dyes, and is expanding into natural colours and titanium-dioxide-free opacity alternatives. The company describes itself as one of the world's top three producers of food colours, cosmetic pigments and fluorescent dyes. Manufacturing is anchored at MIDC Dhatav, Roha (Maharashtra), with a combined 4,625 MTPA capacity including manufacturing partners. A greenfield plant at Saykha, Gujarat was commissioned in March 2024. Wholly owned subsidiaries in the UK, the Netherlands, China and (most recently) the USA provide local stock and technical service. The company says its products reach over 100 countries. Financially it is small (about INR 465 crore consolidated revenue in FY2025) but conservatively run: it has no long-term debt, interest coverage near 50x and an A+/A1+ credit profile. Its central strategic exposure is the global regulatory shift away from petroleum-based synthetic dyes.


What the company does

Neelikon manufactures and sells colourants. These are chemical and, increasingly, natural substances that impart colour to food, beverages, pharmaceuticals, cosmetics, personal care, home care, stationery and inkjet inks, and some industrial applications.

ICRA's company description, repeated across its 2023, 2025 and 2026 rationales, covers dyes for six uses:

  • food

  • pharmaceuticals

  • cosmetics

  • inkjet ink

  • writing ink

  • fluorescent pigments

Trade-show listings from 2025–2026 describe a broader range:

  • US FDA-certified dyes and lakes

  • pigments

  • iron oxides

  • titanium dioxide

  • water-soluble and oil-soluble dyes

  • natural colours

  • titanium-dioxide-free alternatives

  • customised blends

Company's own description (paraphrased)

Neelikon's exhibitor profiles (Maghreb Pharma; Fi Europe 2025) describe it as follows:

  • An ISO 9001, ISO 14001, ISO 45001 and FSSC 22000-certified colour manufacturer serving food, pharmaceutical, cosmetics and personal/home care for more than four decades.

  • Its colours meet European, US, Chinese and Japanese pharmacopoeia standards.

  • It markets a "One World, One Quality" range. These are high-purity colours designed to comply at once with six regulatory frameworks: JECFA, USA, Europe, Japan, China and India.

  • It operates through wholly owned subsidiaries in the USA, Netherlands, UK and China for local stock and technical support.

  • Its products are Halal, Kosher and REACH compliant.

The full annual-report "Business Overview" text is not publicly accessible. The company's website disallows automated access, and the annual report is filed only with the MCA.

Business model and revenue model

Revenue model componentAssessmentBasis
Product sales (B2B manufactured colourants)Effectively 100% of revenueICRA describes operating income from dye/pigment sales; no service or licensing line disclosed
Traded/partner-manufactured productPresent but not quantified. Combined capacity includes "partners", which implies some outsourced/toll manufacturing.ICRA May-2026
Services (custom blending, technical support)Bundled into product pricing; not separately monetised as far as disclosedExhibitor profiles
Subscription / licensingNone disclosed—

Value-chain position

Neelikon sits in the middle of the chain. Upstream are petrochemical-derived intermediates (aromatic amines, sulphonated naphthalene/benzene derivatives and similar) and, for natural colours, plant extracts. Downstream are formulators and brand owners in food, pharma and cosmetics.

The company performs synthesis, purification to food/pharma-grade specifications, laking (precipitation onto alumina substrates), blending and regulatory certification. In the US, batch certification of FD&C colours by FDA is a gatekeeping step that "USFDA certified" grades must pass.

Customer types and channels

ICRA describes a two-tier go-to-market:

Domestic (India): a strong distributor network, plus direct sales to large food, pharmaceutical and personal-care companies.

Export: direct sales into more than 65 countries, with the company's colours present in more than 100 countries through distribution. ICRA's May-2026 rationale gives both figures. Earlier rationales cite "more than 100 countries" for exports.

ICRA credits the company with low customer concentration and a diversified supplier base.

End-markets served

End-marketTypical applicationsProduct families
Food & beverageConfectionery, beverages, bakery, dairy, desserts, seasonings, pet foodFD&C dyes, lakes, blends, natural colours (Neelinatural)
PharmaceuticalsTablet coatings, capsules, syrupsPharma-grade dyes and lakes, iron oxides, TiO2, TiO2-free alternatives
Cosmetics & personal careLipsticks, nail, soaps, shampoosD&C dyes (for example D&C Red 27, D&C Red 33), cosmetic lakes and pigments
Home careDetergents, cleanersWater-soluble dyes
Stationery & inkjet inksWriting inks, inkjetInk-grade dyes
Industrial / fluorescentDaylight fluorescent pigments, specialty applicationsSpecialty fluorescent dyes

Independent characterisation

Neelikon is a mid-sized, export-oriented Indian specialty-chemical SME that has built regulatory credentials (multi-jurisdiction compliance, US FDA certification, FSSC 22000) in a niche where those credentials are the main barrier to entry.

ICRA divides the industry into two parts:

  • a commoditised mass-consumption segment with intense Chinese and Indian competition

  • a concentrated value-added segment where a few large players sell direct to end-users

Neelikon's margin recovery from 12.4% (FY2024) to about 17% (FY2026) has been attributed to a richer product mix and higher domestic share. That suggests it is pivoting toward the value-added end.

The business is structurally exposed to the US-led regulatory move away from petroleum-based dyes. That shift is both a threat to its legacy core and an opening for its natural-colour and TiO2-free lines.

Strategy

No annual-report strategy section, investor day or management commentary is publicly accessible. The strategic themes below are inferred from verifiable actions and third-party descriptions.

Observable strategic themes

ThemeEvidenceAssessment
Move up the value chainICRA cites a "favourable product mix" and value-added products as margin drivers. The Saykha conversion capex targets value-added products.The main margin lever since FY2024
Global regulatory harmonisation as a selling point"One World, One Quality" range compliant with six frameworksDifferentiator versus commodity Chinese and Indian suppliers
Natural colours diversificationNeelinatural range, marketed at Fi Europe 2025 and in a June-2026 brochureDefensive and offensive response to synthetic-dye regulation
TiO2-free alternativesListed in 2025–2026 exhibitor profilesResponse to EU E171 restriction and pharma reformulation
Direct market presenceFourth subsidiary added (USA)Captures distributor margin; closer to US reformulation demand
Domestic mix shiftHigher domestic share supporting FY2026 realisationsHedge against export price competition
Financial conservatismNo term debt; capex fully from internal accruals; no dividends expectedPreserves optionality; ICRA's downgrade trigger is TD/OPBDITA above 1.5x

Initiatives in the last 24 months (Oct-2024 to Oct-2026)

InitiativeDateDetailSource
Saykha plant reconfiguration capexAnnounced by Mar-2025; FY2026–FY2027About INR 60 crore to modify the plant for higher value-added products, funded internally. By May-2026 ICRA describes this capex as "being optimised".ICRA Mar-2025; May-2026
USA subsidiaryBy May-2026Neelikon Colors Global USA Inc. added to consolidationICRA May-2026
Enhanced bank limitsMay-2026Rated limits raised by INR 30 crore to INR 134.75 crore, signalling expected working-capital growthICRA May-2026
Natural colours marketing pushDec-2025 to Jun-2026Fi Europe 2025; Neelinatural brochureIngredients Network

Medium-term targets / guidance

Not publicly disclosed. ICRA's forward view (May-2026) expects stable cash flows, comfortable liquidity, limited repayment obligations and no dividends. It flags West Asia conflict-driven chemical price inflation as a key monitorable.

ESG commitments

ISO 14001 (environmental management) and ISO 45001 (occupational health and safety) certifications are held. No quantified emissions or sustainability targets have been published.

Products & Services

The company does not publish a full price list or launch-year data. The catalogue below is built from exhibitor profiles, ingredient databases (SpecialChem, COPTIS, Ingredients Network) and ICRA descriptions. Pricing is not publicly disclosed for any line; all are sold B2B on negotiated or quoted terms.

Synthetic food, drug & cosmetic colours

Product lineDescription / specificationTarget customerFlagship / named itemsSource
US FDA-certified FD&C dyesWater-soluble synthetic dyes batch-certified for US food, drug and cosmetic useUS-bound food, pharma and cosmetic formulatorsFD&C range (specific CI numbers not enumerated publicly)Maghreb Pharma listing
D&C dyesDrug & Cosmetic grade dyesCosmetics, personal careD&C Red 27 (CI 45410), D&C Red 33 (CI 17200)SpecialChem
"Neelicol" branded dyesBranded synthetic dye rangeFood, cosmeticsNeelicol Black PN (CI 28440)SpecialChem
"One World, One Quality" coloursHigh-purity grades designed to meet JECFA, US, EU, Japan, China and India specifications at onceMultinational food and pharma companies seeking one global SKURange nameMaghreb Pharma listing
Lakes (aluminium lakes)Insoluble pigment forms of dyes for oil/fat systems, coatings and tabletsConfectionery, tablet coating, cosmeticsUS FDA-certified lakes; cosmetic lakesMaghreb Pharma; a-leads
GranularsDust-free granulated colour formsFood/pharma manufacturersNot namedFi Europe listing
Water-soluble coloursStandard soluble dyesBeverages, home care, foodNot namedExhibitor profiles
Oil-soluble coloursFat- and solvent-soluble dyesFats, waxes, cosmeticsNot namedExhibitor profiles
Customised blendsShade-matched blends of primariesBrand owners needing specific shadesBespokeExhibitor profiles

Inorganic pigments and opacifiers

Product lineDescriptionTarget customerSource
Iron oxidesRed, yellow and black iron oxide pigmentsPharma coatings, cosmeticsMaghreb Pharma listing
Titanium dioxideWhite opacifierPharma coatings, cosmeticsMaghreb Pharma listing
Titanium-dioxide-free alternativesOpacity systems that replace TiO2, which is no longer authorised as a food additive (E171) in the EUEU food and pharma reformulatorsMaghreb Pharma; Fi Europe listing
Cosmetic pigmentsPigments for decorative cosmeticsColour-cosmetics brandsa-leads; COPTIS

Natural colours

Product lineDescriptionApplicationsLatest dated referenceSource
NeelinaturalNatural colours extracted from plants, fruits and vegetables; includes custom natural blends. Supplier categories cited include anthocyanins, beetroot red/betanin and carotenes.Confectionery, bakery, desserts, dairy, seasonings, beverages, pet food, pharma, cosmeticsBrochure dated 22-Jun-2026Ingredients Network

Specialty / industrial

Product lineDescriptionTarget customerSource
Specialty fluorescent dyesDyes used to make daylight fluorescent pigments and in specialty industrial usesPigment makers, industrial usersCOPTIS; ICRA
Daylight fluorescent pigmentsFluorescent pigment productsInks, coatings, plasticsa-leads
Inkjet ink dyesHigh-purity dyes for inkjet formulationsInk formulatorsICRA; COPTIS
Writing ink dyesDyes for stationery inksStationery makersICRA

Certifications and compliance (cross-portfolio)

ISO 9001, ISO 14001, ISO 45001, FSSC 22000, Halal, Kosher, REACH. The company says its pharma grades meet European, US, Chinese and Japanese pharmacopoeia standards (Maghreb Pharma listing).

Financial Narrative

FY2021 data was not found in any accessible public source, so the five-year window used here is FY2022–FY2026. FY2026 consolidated figures are not yet published; only standalone provisional figures are available.

Gross profit, EPS, dividends per share, balance-sheet line items, capex and cash-flow statements are not publicly disclosed outside MCA filings.

Income statement — consolidated (reported)

Blank = not publicly disclosed. FY2023 PAT discrepancy: 44.6 (Dec-2023 rationale, PAT/OI 10.6%) vs 41.2 (Mar-2025 rationale, PAT/OI 9.8%). The later figure is used for the margin row.

Income statement — standalone (reported)

FY2026 provisional. Source: ICRA May-2026: ### Derived metrics (arithmetic from ICRA ratios — labelled as derived)

How these were derived: EBITDA = operating income × OPBDIT/OI: - Implied interest = EBITDA ÷ interest coverage.

  • Implied debt = EBITDA × Total debt/OPBDIT, using the precise ratios ICRA quotes in text where available (0.71x FY2022, 0.78x FY2023, 0.67x FY2024). Otherwise the rounded table ratio is used (0.7x FY2025 consolidated; 0.4x and 0.6x standalone).

  • Debt figures are rounded approximations. ICRA confirms the company has no long-term debt, so implied debt is essentially working-capital borrowing.

Growth

Revenue CAGR: Consolidated FY2022–FY2025 is about 0.9% a year (452.4 to 464.9). On this evidence, the business has not grown in nominal terms from its FY2022 peak. Recovery since FY2024 has been margin-led rather than volume-led.

Liquidity datapoints

Net debt: Implied FY2026 standalone debt of about INR 32 crore against INR 106.9 crore cash gives an implied net cash of about INR 75 crore. This is a derived approximation.

Items not publicly disclosed

Gross profit; operating income (EBIT); pre-tax income; EPS (basic/diluted); dividends per share; total assets (EMIS reports only +16.5% growth in 2025, without the base); equity/net worth in absolute terms; goodwill and intangibles; working capital in absolute terms; operating cash flow, capex and free cash flow by year (beyond the Saykha capex of about INR 130 crore and planned capex of about INR 60 crore); buybacks; ROE, ROA and ROIC; current ratio; asset turnover; cash conversion cycle. All of these are available in MCA AOC-4 filings, which can be bought through MCA21 or data vendors (EMIS, Tofler).

Commentary on trends, inflections and drivers

FY2022 (peak). A 20.1% OPBDIT margin and INR 70.2 crore PAT on INR 452.4 crore revenue marked the cyclical high. This matches the post-COVID restocking boom across Indian specialty chemicals and peers. For comparison, listed peer Vidhi Specialty reported its highest revenue (about INR 537 crore) in the same year.

FY2023 (inflection down). Revenue fell about 7%. ICRA attributes this to weaker export demand as developed-market macro conditions deteriorated, and to rising supply from Chinese producers. Margin nearly halved to 12.4%, and interest coverage dropped from 57.6x to 19.2x as working-capital borrowing costs rose. The step-down was industry-wide: Vidhi's FY2023 revenue fell about 25%.

FY2024 (trough, stabilisation). Revenue was flat. ICRA describes volume growth offset by lower realisations, with the company passing raw-material deflation through to customers. Margin held at 12.4%, and end-user inventory destocking continued. The Saykha greenfield plant was commissioned in March 2024 at about INR 130 crore, funded entirely from internal accruals. Even so, debt/OPBDIT improved to 0.67x, a sign of strong cash generation.

FY2025 (recovery). Revenue grew about 9.8% to INR 464.9 crore, and margin expanded about 380 basis points to 16.2%. ICRA attributes the improvement to better realisations and a more favourable product mix. PAT rose about 41% to INR 53.7 crore.

FY2026 (margin expansion continues; growth slows). Standalone revenue rose only about 3% to INR 462.8 crore (provisional). Standalone OPBDIT margin, however, reached 17.3%, the highest in the visible series apart from FY2022. ICRA cites a higher share of domestic sales, which carry better realisations, and cost efficiencies. Standalone PAT fell about 8% to INR 46.2 crore despite the higher EBITDA. Likely causes include higher depreciation from the Saykha plant and possibly lower other income or a higher tax rate; this is not disclosed and is inferred only. Cash rose to INR 106.9 crore.

Overall. The company has shown durable cash generation through a full down-cycle while funding a plant equal to about 30% of a year's revenue without term debt. The open question is top-line growth. Revenue is flat versus FY2022, and the Saykha asset is under-utilised.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (As Reported) Overview

Segment (as reported)ContentsSegment revenueSegment marginStatus

Colourants (single segment, inferred)

Synthetic food/drug/cosmetic dyes, lakes, pigments, iron oxides, TiO2 and alternatives, natural colours, fluorescent dyes, ink dyes

Equals total operating income (see below)

Equals company OPBDIT margin

Inferred; not formally disclosed

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Colourants revenue consolidated (INR Cr)

452.4421.4423.5464.9—

Colourants revenue standalone (INR Cr)

——402.7449.2462.8

YoY growth consolidated (%)

—-6.90.59.8—

YoY growth standalone (%)

———11.53.0

OPBDIT margin consolidated (%)

20.112.412.416.2—

OPBDIT margin standalone (%)

——11.815.517.3

Group Entities

EntityCountryOwnershipRoleSource

Neelikon Food Dyes and Chemicals Ltd

India

Parent

Manufacturing (Roha, Saykha), domestic and export sales

ICRA

Shanghai Neelikon Food Dyes & Chemicals Ltd

China

100%

China sales, stock and technical support

ICRA May-2026

Neelikon Food Dyes & Chemicals (Europe) Ltd (trades as Neelikon Specialities Europe Ltd)

UK

100%

UK/EU sales and stockholding

ICRA; COPTIS

Neelikon Food Dyes & Chemicals (Netherlands) / Neelikon Specialities Europe B.V.

Netherlands

100%

EU sales hub; trade-show presence

ICRA; Fi Europe listing

Neelikon Colors Global USA Inc.

USA

100%

US sales, stock and support; first consolidated in the May-2026 rationale

ICRA May-2026; EMIS

Key Financials and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Operating income (INR Cr)

452.4421.4423.5464.9

PAT (INR Cr, per ICRA Dec-2023)

70.244.6——

PAT (INR Cr, per ICRA Mar-2025 and May-2026)

—41.238.253.7

OPBDIT margin (%)

20.112.412.416.2

PAT margin (%)

15.59.89.011.6

Key Financials and Margin Analysis (%) (FY2024–FY2026)

MetricFY2024FY2025FY2026

Operating income (INR Cr)

402.7449.2462.8

PAT (INR Cr)

35.350.146.2

OPBDIT margin (%)

11.815.517.3

PAT margin (%)

8.811.110.0

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA consolidated derived (INR Cr)

90.952.352.575.3—

EBITDA standalone derived (INR Cr)

——47.569.680.1

Implied interest consolidated derived (INR Cr)

1.62.71.31.5—

Implied total debt consolidated derived (INR Cr)

64.540.835.252.7—

Implied total debt standalone derived (INR Cr)

——19.041.832.0

Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026

Consolidated revenue growth YoY (%)

-6.90.59.8—

Consolidated PAT growth YoY (%, restated base)

-41.3-7.340.6—

Standalone revenue growth YoY (%)

——11.53.0

Standalone PAT growth YoY (%)

——41.9-7.8

Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

TOL/TNW consolidated (x)

0.40.30.20.3—

TOL/TNW standalone (x)

——0.20.30.2

Total debt/OPBDIT consolidated (x)

0.710.780.670.7—

Total debt/OPBDIT standalone (x)

——0.40.60.4

Interest coverage consolidated (x)

57.619.241.749.9—

Interest coverage standalone (x)

——39.850.746.2

Valuation Snapshot

MetricValueAs at / periodSource

Unencumbered cash (standalone)

INR 67.5 crore

30-Sep-2023

ICRA Dec-2023

Unencumbered cash (standalone)

INR 86.1 crore

31-Mar-2024

ICRA Mar-2025

Unencumbered cash (standalone, provisional)

INR 106.9 crore

31-Mar-2026

ICRA May-2026

Average fund-based limit utilisation

49% of INR 89 crore limits

12 months to Aug-2023

ICRA Dec-2023

Average fund-based limit utilisation

22% of INR 99 crore limits

12 months to Sep-2024

ICRA Mar-2025

Average fund-based limit utilisation

about 24% of INR 129 crore limits

12 months to Dec-2025

ICRA May-2026

Fund flow from operations

INR 38–40 crore a year

FY2023–FY2024 (expected similar FY2025–FY2026)

ICRA Mar-2025

Cash accruals

INR 50–55 crore a year

Recent years (FY2025–FY2026)

ICRA May-2026

Dividend payout

None expected ("no dividend payouts")

Forward-looking

ICRA May-2026

Geographic Revenue

IndicatorEvidenceSource

Export breadth

Direct export sales to more than 65 countries; colours present in more than 100 countries

ICRA May-2026

Export weakness FY2023–FY2024

Subdued export demand and Chinese supply pressure

ICRA Dec-2023

Domestic share rising (FY2026)

ICRA cites a higher share of domestic sales commanding better realisations as a margin driver

ICRA May-2026

Subsidiary footprint

UK, Netherlands (Europe); Shanghai (China); USA (new)

ICRA May-2026

North America route-to-market history

Spectra Colors exclusive US/Canada distributor from 2005; now supplemented or replaced by its own US subsidiary (relationship status today not publicly disclosed)

Happi 2005; ICRA May-2026

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable (unlisted)

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not applicable / not publicly disclosed

Dividend history

Not publicly disclosed; ICRA expects no dividend payouts going forward

Buyback authorisations

None disclosed

Analyst Ratings & Targets

DateLong-term ratingShort-term ratingTotal rated (INR Cr)

30-Jun-2021

A+ (Stable)

A1

—

27-Sep-2022

A+ (Stable)

A1

—

17-Nov-2022

A+ (Stable)

A1

—

21-Dec-2023

A+ (Stable)

A1

104.75

17-Mar-2025

A+ (Stable)

A1

104.75

25-May-2026

A+ (Stable)

A1+ (upgraded)

134.75

“—” = not publicly disclosed.

Debt Facilities

FacilityAmount (INR Cr)Rating

Long-term fund-based cash credit

15.00

A+ (Stable)

Short-term fund/non-fund based WC limits

116.50

A1+

LT/ST fund/non-fund based others (sub-limit)

(131.50)

A+ (Stable)/A1+

Short-term non-fund based forward cover

3.25

A1+

Total

134.75

—

Capital Markets Data

MetricFY2024FY2025FY2026FY2027

Total rated bank limits (INR Cr)

104.75104.75104.75134.75

Analyst Conclusions

Management guidance

Not publicly disclosed. ICRA's stable outlook rests on its expectation of stable cash flow from operations, comfortable liquidity, limited repayments and no dividend outflows. It names the West Asia-driven chemical price run-up as a monitorable.

Consensus

None; no sell-side coverage.

Bull case

  1. The margin structure has reset higher. OPBDIT moved from 12.4% to about 17% in two years on mix and domestic share, and EBITDA reached about INR 80 crore in FY2026 (standalone, derived). If Saykha's value-added conversion delivers, margins near 18–20% (FY2022-like) are plausible without heavy volume growth.

  2. Regulation can be monetised. The FDA phase-out pushes US brand owners toward natural colours. With Neelinatural, TiO2-free lines, multi-jurisdiction compliance and a new US subsidiary, Neelikon is positioned to capture reformulation spend rather than only lose synthetic volume.

  3. The balance sheet is a strategic weapon. With about INR 107 crore of cash, about INR 75 crore implied net cash and coverage near 50x, the company can fund natural-colour capacity or acquire a natural-extraction business without equity dilution. ICRA's downgrade trigger (above 1.5x TD/OPBDITA) leaves room for meaningful debt-funded growth if needed.

Bear case

  1. Structural decline in the core. Petroleum-based synthetic dyes are Neelikon's historic franchise. US food use is being phased out, FDA scrutiny has spread to drugs, and Congress is legislating. Natural colours are a different business, with agricultural sourcing, lower purity control and different leaders (Oterra, Sensient, Givaudan), where Neelikon has no demonstrated scale.

  2. No growth for four years. FY2025 consolidated revenue (INR 464.9 crore) barely exceeds FY2022's, and FY2026 standalone growth was about 3%. The listed peer just posted +66% quarterly growth, which raises the question of whether Neelikon is losing share in the China+1 window.

  3. Capital-allocation execution. About INR 130 crore was spent on Saykha, ICRA judged the ramp-up sub-optimal, and another INR 60 crore was earmarked to fix it. Combined with PAT falling in FY2026 despite higher EBITDA, returns on recent capex appear weak. Opaque disclosure makes this hard to monitor.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersExpected timing
FY2026 audited consolidated results (MCA / next ICRA review)Confirms provisional margin and the PAT trajectory; first full year with the US subsidiaryLate 2026 to 2027
US FDA end-2026 phase-out deadline and any Congressional statuteDetermines US synthetic food-dye volume lossDec-2026 onward
Saykha utilisation and conversion capex completionReturn on about INR 190 crore of cumulative investmentFY2027
Natural colours revenue disclosure (if any)Evidence of pivot tractionOngoing
West Asia conflict / chemical input pricesMargin risk given high inventoryOngoing
Use of enhanced bank limits (INR 134.75 crore)Signals working-capital build for growthFY2027
Peer (Vidhi) growth versus NeelikonMarket-share signalQuarterly
Next ICRA surveillancePossible long-term upgrade if scale improvesAbout mid-2027

Concluding analyst verdict

Neelikon Food Dyes and Chemicals is a financially disciplined, promoter-run specialty colourant maker whose credit quality is clearly better than its growth profile. The evidence is consistent across three ICRA reviews.

The company came through a severe FY2023–FY2024 industry downturn without stress. It funded a INR 130 crore greenfield plant entirely from internal accruals, kept zero term debt, and emerged with record cash (INR 106.9 crore) and an upgraded A1+ short-term rating. Margin recovery to about 17% shows that the value-added and domestic-mix strategy works.

The equity-style questions are less comfortable. Revenue has been essentially flat since FY2022, and the new Saykha capacity needed a second round of capex after a weak ramp-up. Standalone PAT fell in FY2026 even as EBITDA rose. Above all, the US is moving decisively to remove petroleum-based synthetic dyes from food, with signs of spill-over into drugs and the possibility of statute. For a company built on certified synthetic colours, that is a franchise-level change, not a cyclical one.

Neelikon has responded sensibly with Neelinatural, TiO2-free lines, multi-jurisdiction products and a US subsidiary. However, no public data shows how much of revenue these new lines represent. Natural colours are also a crowded field with well-capitalised incumbents.

Verdict: From a credit perspective Neelikon is low-risk and stable to improving. From a strategic and equity perspective it is a "show-me" story. Its balance sheet buys time and options. Its future value depends on turning regulatory disruption into natural- and clean-label colour growth before synthetic volumes erode. Investors, counterparties or acquirers should obtain the FY2025–FY2026 MCA filings for segment, geographic and product-mix data before forming a firmer view, because public disclosure is too thin for higher-conviction conclusions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitle / roleTenureBackgroundSource

Mukund Turakhia

Founder and promoter

Since 1983

Chemical engineer; over 50 years in the dyestuff and chemical industry

ICRA rationales

Satyen Turakhia

Director

—

Not disclosed (presumed promoter family)

a-leads aggregator

“—” = not publicly disclosed.

Major Shareholders

Holder categoryStakeSource

Promoter family (Turakhia) / natural persons

Not publicly disclosed; LEI records the ultimate parent as natural persons, with no corporate parent

Bloomberg LEI

Institutional investors

None identified; no PE/VC funding rounds found

—

Top-10 holders

Not applicable / not publicly disclosed

—

Competitive Landscape

Key Competitors

CompetitorHQListingOverlap with NeelikonRevenue (latest available)Source / note

Vidhi Specialty Food Ingredients Ltd

Mumbai, India

BSE: 531717

Synthetic food colours, natural colours; describes itself as the 2nd-largest food colour maker in Asia and 3rd-largest globally; also a Roha MIDC presence

INR 380.0 crore (FY2026, consolidated)

Exchange filings via 5paisa / StockAnalysis

Sensient Technologies (Sensient Colors)

Milwaukee, USA

NYSE: SXT

Food, pharma and cosmetic colours, synthetic and natural; global leader in value-added colours

—

Named as a major food dye producer in Nexstar reporting

Oterra (formerly Chr. Hansen Natural Colors)

Copenhagen, Denmark

Private

Natural colours

—

Oterra press releases

Roha Dyechem

Mumbai, India

Private

Synthetic and natural food colours, lakes

——

Koel Colours

Mumbai, India

Private

Food, drug and cosmetic colours

——

Dynemic Products Ltd

Ahmedabad, India

Listed (BSE/NSE)

Food colours and lakes

—

Industry knowledge

Chinese synthetic food colour producers (multiple)

China

Various

Mass-consumption synthetic colours

—

ICRA cites rising Chinese supply

Givaudan (natural colours, through acquired businesses)

Switzerland

SIX

Natural colours

—

Industry knowledge

Pharma coating / colour specialists (for example Colorcon)

USA

Private

Pharma colours, TiO2-free coatings

—

Industry knowledge

Fluorescent pigment makers (for example DayGlo / Sun Chemical)

USA

Private (DIC group)

Fluorescent dyes and pigments (customer and competitor)

—

Industry knowledge

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricFY2022FY2023FY2024FY2025FY2026

Neelikon revenue consolidated (INR Cr)

452.4421.4423.5464.9—

Vidhi revenue (INR Cr)

537.1404.0298.0382.3380.0

Neelikon OPBDIT margin (%)

20.112.412.416.2—

Vidhi operating income margin (%)

15.313.017.215.918.1

Neelikon PAT (INR Cr)

70.241.238.253.7—

Vidhi PAT (INR Cr)

58.637.736.443.449.0

Recent Developments

Material industry and regulatory events that directly affect the company are included and flagged (Industry).

Company Snapshot

261

Employees

1983

Founded

Maharashtra, India

Headquarters

SWOT Analysis

Strengths

  • Very strong balance sheet: No long-term debt; TOL/TNW 0.2x; standalone total debt/OPBDIT 0.4x (FY2026 provisional) — ICRA May-2026
  • Exceptional debt servicing capacity: Interest coverage 49.9x consolidated (FY2025) and 46.2x standalone (FY2026) — ICRA
  • Rising liquidity: Standalone cash grew from INR 67.5 crore (Sep-2023) to INR 106.9 crore (Mar-2026); limit utilisation about 24% — ICRA
  • Margin recovery: OPBDIT margin rose from 12.4% (FY2024) to 16.2% (FY2025) consolidated and 17.3% (FY2026) standalone — ICRA
  • Diversified customers and geographies: Low customer concentration; direct exports to more than 65 countries; presence in more than 100 — ICRA May-2026
  • Credentials and certifications: ISO 9001/14001/45001, FSSC 22000, Halal, Kosher, REACH; six-framework compliant range — Maghreb Pharma listing
  • Credit quality upgrade: Short-term rating raised to A1+ on 25-May-2026 — ICRA
  • Self-funded expansion capability: INR 130 crore Saykha plant funded entirely from internal accruals — ICRA Mar-2025

Weaknesses

  • Flat long-term top line: Consolidated revenue FY2022 INR 452.4 crore vs FY2025 INR 464.9 crore (CAGR about 0.9%) — ICRA
  • Under-utilised new asset: ICRA (Mar-2025) describes the Saykha revenue ramp-up as sub-optimal because of unfavourable conditions for some products
  • Inventory-heavy working capital: ICRA repeatedly cites high inventory levels and working-capital intensity
  • Small scale versus global leaders: About INR 465 crore revenue against multinational colour majors
  • Limited transparency: Unlisted; no published annual report, segment or geographic data; data inconsistencies (FY2023 PAT 44.6 vs 41.2; employees 261 vs 133)
  • Profit did not track EBITDA in FY2026: Standalone PAT fell from INR 50.1 crore to INR 46.2 crore while OPBDIT margin rose to 17.3% — ICRA May-2026

Opportunities

  • Natural colours demand from US reformulation: FDA's plan includes authorising four new natural colour additives; Neelinatural range launched — Nexstar; Ingredients Network
  • TiO2 replacement: EU E171 restriction; TiO2-free alternatives in portfolio — exhibitor profiles
  • Direct US presence: Neelikon Colors Global USA Inc. now consolidated — ICRA May-2026
  • Saykha value-added conversion: About INR 60 crore planned to shift to higher-value products — ICRA Mar-2025
  • Domestic market mix: A higher domestic share supported FY2026 realisations — ICRA May-2026
  • China+1 sourcing: Peer Vidhi's Q1 FY2027 revenue +66% YoY suggests strong demand for Indian food colours — Vidhi Jul-2026 presentation
  • Headroom for growth capital: Rated limits raised to INR 134.75 crore; downgrade trigger only above 1.5x TD/OPBDITA — ICRA

Threats

  • US synthetic food dye phase-out: Six FD&C dyes targeted for elimination from food by end-2026 — FDA via McDermott/Akin Gump
  • Spill-over to drugs: FDA draft guidance on synthetic dyes in drugs (29-May-2025)
  • Escalating US regulation: Further FDA steps (22-Jul-2026) and Congressional legislation — Akin Gump
  • Chinese price competition: Cited as a driver of the FY2023 downturn — ICRA Dec-2023
  • Input-cost shock: West Asia conflict driving chemical price run-up — ICRA May-2026
  • Peer outperformance: Vidhi Q1 FY2027 revenue +66%, against Neelikon FY2026 standalone growth of about 3%

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
17-Mar-2025ICRA reaffirms A+ (Stable)/A1; discloses Saykha ramp-up shortfall and about INR 60 crore conversion capex planFirst public disclosure that the INR 130 crore plant was under-performing
22-Apr-2025*(Industry)* HHS/FDA announce a phase-out of petroleum-based synthetic food dyes by end-2026: revocation for Citrus Red No. 2 and Orange B; voluntary elimination of six FD&C dyes; earlier removal of Red No. 3; four new natural colour additives to be authorised McDermott; Akin Gump; NexstarDirect threat to US food-grade FD&C volumes; opportunity for natural colours
29-May-2025*(Industry)* FDA extends synthetic-dye reduction effort to drug products through draft guidance McDermottPharma colour demand also at risk in the US over time
FY2025 close (Mar-2025)Consolidated revenue INR 464.9 crore (+9.8%), PAT INR 53.7 crore, margin 16.2% ICRA May-2026Confirms recovery from the FY2023–FY2024 trough
2025 (EMIS)EMIS records net sales up 9.77% and total assets up 16.5% for 2025; employees 261Independent corroboration of FY2025 growth
2–4 Dec-2025Exhibits at Fi Europe 2025, Paris, through Neelikon Specialities Europe B.V. Ingredients NetworkEuropean natural colours and TiO2-free push
FY2026 close (Mar-2026)Standalone revenue INR 462.8 crore, margin 17.3%, cash INR 106.9 crore (provisional) ICRA May-2026Margin at multi-year high; growth slowing
25-May-2026ICRA upgrades short-term rating to A1+, reaffirms A+ (Stable), raises rated limits to INR 134.75 crore; flags West Asia conflict chemical price run-up as a key monitorableCredit-quality improvement; input-cost risk flagged
By 25-May-2026Neelikon Colors Global USA Inc. enters the consolidation perimeter ICRA May-2026Direct US presence established
22-Jun-2026Neelinatural natural food colours brochure published Ingredients NetworkNatural colours commercial rollout
30-Jun-2026EMIS profile updated with 2025 financial dataData availability
22-Jul-2026*(Industry)* FDA announces two additional steps in its petroleum-based colour additive phase-out; Congress has introduced legislation targeting common food dyes Akin Gump "Eye on FDA"The regulatory headwind is intensifying, not fading
Q1 FY2027 (Apr–Jun 2026)*(Industry peer)* Listed peer Vidhi Specialty reports revenue of INR 146.3 crore (+66.4% YoY) and PAT of INR 17.15 crore (+34.7% YoY) Vidhi investor presentation, Jul-2026Suggests strong near-term demand and realisations in Indian food-colour exports, possibly as US/EU buyers re-source or build inventory

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment: Colourants revenue consolidated rose from INR 4,524 Mn in FY2022 to INR 4,649 Mn in FY2025.
Neelikon Food Dyes & Chemicals Ltd. — Revenue by Segment
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Colourants revenue consolidated4,5244,2144,2354,649—
Colourants revenue standalone——4,0274,4924,628

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1ICRA rating rationale: Neelikon Food Dyes and Chemicals Ltd — 25-May-2026 (icra.in)
  2. 2ICRA rating rationale: Neelikon Food Dyes and Chemicals Ltd — 17-Mar-2025 (icra.in)
  3. 3ICRA rating rationale: Neelikon Food Dyes and Chemicals Ltd — 21-Dec-2023 (icra.in)
  4. 4Bloomberg LEI record 3358006S7LN89RRJYO87 — Accessed Oct-2026 (lei.bloomberg.com)
  5. 5GST registry (KnowYourGST) — Accessed Oct-2026 (knowyourgst.com)
  6. 6EMIS company profile — Updated 30-Jun-2026 (emis.com)
  7. 7a-leads company profile — Accessed Oct-2026 (a-leads.co)
  8. 8COPTIS supplier listing — Accessed Oct-2026 (coptis.com)
  9. 9SpecialChem supplier page — Accessed Oct-2026 (specialchem.com)
  10. 10Maghreb Pharma exhibitor profile — Accessed Oct-2026 (maghrebpharma.com)
  11. 11Ingredients Network: Fi Europe 2025 exhibitor — Dec-2025 (ingredientsnetwork.com)
  12. 12Ingredients Network: Neelinatural brochure — 22-Jun-2026 (ingredientsnetwork.com)
  13. 13Happi: Neelikon partners with Spectra Colors — 9-Dec-2005 (happi.com)
  14. 14PharmaNow company listing — Accessed Oct-2026 (pharmanow.live)
  15. 15McDermott Will & Emery: FDA synthetic dye phase-out — 2025 (mwe.com)
  16. 16Akin Gump "Eye on FDA": HHS/FDA phase-out — Updated 2026 (akingump.com)
  17. 17Nexstar: Which food dyes are expected to be eliminated — Apr-2025 (yahoo.com)
  18. 18Packaging Law: HHS and FDA phase-out — 2025 (packaginglaw.com)
  19. 19StockAnalysis: Vidhi Specialty income statement — Jul-2026 (stockanalysis.com)
  20. 205paisa: Vidhi FY2026 results — 2026 (5paisa.com)
  21. 21Vidhi Q1 FY2027 investor presentation (NSE) — 29-Jul-2026 (nsearchives.nseindia.com)
  22. 22Screener: Vidhi Specialty — Accessed Oct-2026 (screener.in)
  23. 23Oterra Color Trends 2025 press release — 29-Jan-2025 (mb.cision.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.